Copyright
©The Author(s) 2017.
World J Clin Oncol. Aug 10, 2017; 8(4): 320-328
Published online Aug 10, 2017. doi: 10.5306/wjco.v8.i4.320
Published online Aug 10, 2017. doi: 10.5306/wjco.v8.i4.320
Author/study | Marker antibody | Tumor type | Treatment line | PD-L1 cutoff | N pts | Response (%) | mPFS mo (95%CI) | mOS mo (95%CI) |
Nivolumab | ||||||||
Gettinger et al[8] Phase I | Dako 28-8 | NSCLC | > 2 | ≥ 5 % | 33 | 15 | 3.3 (1.8-7.5) | 7.8 (5.6-21.7) |
< 5% | 35 | 14 | 1.8 (1.7-2.3) | 10.5 (5.2-14.8) | ||||
Rizvi et al[9] CM 063 Phase II | Dako 28-8 | Squamous | ≥ 2 | ≥ 5% | 25 | 24 | NR | NR |
NSCLC | < 5% | 51 | 14 | NR | NR | |||
Brahmer et al[10] CM 017 Phase III | Dako 28-8 | Squamous | > 1 | ≥ 10% | 36 | 19 | 3.7 (NR) | 11 (NR) |
NSCLC | < 10% | 81 | 16 | 2.3 (NR) | 8.2 (NR) | |||
≥ 5% | 42 | 21 | 4.8 (NR) | 10 (NR) | ||||
< 5% | 75 | 15 | 2.2 (NR) | 8.5 (NR) | ||||
≥ 1% | 63 | 17 | 3.3 (NR) | 9.3 (NR) | ||||
< 1% | 54 | 17 | 3.1 (NR) | 8.7 (NR) | ||||
Borgheai et al[11] CM 057 Phase III | Dako 28-8 | Non squamous | > 1 | ≥ 10% | 86 | 37 | 5.0 (NR) | 19.9 (NR) |
NSCLC | < 10% | 145 | 11 | 2.1 (NR) | 9.9 (NR) | |||
≥ 5% | 95 | 34 | 5.0 (NR) | 19.4 (NR) | ||||
< 5% | 136 | 14 | 2.1 (NR) | 9.8 (NR) | ||||
≥ 1% | 123 | 31 | 4.2 (NR) | 17.7 (NR) | ||||
< 1% | 108 | 9 | 2.1 (NR) | 10.5 (NR) | ||||
Gettinger et al[12] CM 012 Phase I | Dako 28-8 | NSCLC | 1 | ≥ 50% | 12 | 50 | NR | NR |
< 50% | 34 | 15 | NR | NR | ||||
≥ 25% | 18 | 44 | NR | NR | ||||
< 25% | 28 | 11 | NR | NR | ||||
≥ 10% | 20 | 40 | NR | NR | ||||
< 10% | 26 | 12 | NR | NR | ||||
≥ 5% | 26 | 31 | NR | NR | ||||
< 5% | 20 | 15 | NR | NR | ||||
≥ 1% | 32 | 28 | NR | NR | ||||
< 1% | 14 | 14 | NR | NR | ||||
Rizvi et al[13] CM012 Phase I | Dako 28-8 | NSCLC | 1 | ≥ 1% | 23 | 48 | 6.0 (< 0.1+-21.8) | 20.2 (6.2-28.8+) |
< 1% | 21 | 43 | 5.2 (0.9+-28.7+) | 19.2 (4.5-29.7+) | ||||
Socinski et al[14] CM 026 Phase III | Dako 28-8 | NSCLC | 1 | ≥ 5% | NR | 76.80 | NR | NR |
< 5% | NR | NR | NR | NR | ||||
≥ 25% | NR | 48.70 | NR | NR | ||||
< 25% | NR | NR | NR | NR | ||||
≥ 50% | NR | 32.50 | NR | NR | ||||
< 50% | NR | NR | NR | NR | ||||
≥ 75% | NR | 20.70 | NR | NR | ||||
< 75% | NR | NR | NR | NR |
- Citation: Tibaldi C, Lunghi A, Baldini E. Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors. World J Clin Oncol 2017; 8(4): 320-328
- URL: https://www.wjgnet.com/2218-4333/full/v8/i4/320.htm
- DOI: https://dx.doi.org/10.5306/wjco.v8.i4.320